Skip to main content
SpringerLink
Log in

Altbewährte Substanz mit neuer Galenik

  • Literatur kompakt
  • Published:
DNP - Der Neurologe und Psychiater Aims and scope

Beta-Interferon-Behandlungen sind seit über 20 Jahren eine sichere und wirksame Therapie der schubförmigen Multiplen Sklerose. Eine Neuerung der Galenik, die pegylierte Form des Interferon-beta 1a, ist seit September in Deutschland verfügbar.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Calabresi PA et al. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014;13(7):657–65

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Martin Marziniak

Authors
  1. Martin Marziniak
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marziniak, M. Altbewährte Substanz mit neuer Galenik. DNP 15, 25–26 (2014). https://doi.org/10.1007/s15202-014-0960-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15202-014-0960-1

Search

Navigation